View Another Service

Clinical Trials

Clinical trials are the final step in a long process that often begins in the lab. Many cancer treatments used today are results of past clinical trials. Clinical trials are key to developing new methods to prevent, detect, and treat cancer. It is through clinical trials that researchers can determine whether new treatments are safe and effective and work better than current treatments. When you take part in a clinical trial, you add to our knowledge about cancer and help improve cancer care. For more information about clinical trials, click this link provided by the National Cancer Institute.

The Bassett Cancer Institute has been providing access to cutting edge treatments in a convenient, local setting for over 40 years. Bassett's membership in the Eastern Cooperative Oncology Group (ECOG) allows access to numerous clinical trials through the Clinical Trials Support Unit (CTSU), funded by The National Institutes of Health (NIH) and The National Cancer Institutes (NCI).

ACT (About Clinical Trials) is a website to help empower people to understand cancer clinical trials and discuss this option with their doctors and loved ones. This unique resource features unscripted interviews with clinical trial participants, doctors, patient rights advocates, and others. Their honest stories and the information on this site will help you ACT toward having informed discussions with those committed to your care.

For more information regarding ACT, please follow this link and explore.


Learn more about Bassett's Cancer Clinical Trials program by clicking here, where patients tell their stories.

 

Breast Cancer

 

NSABP B-51: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy.

For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
 

(Project 1056)
Joy Anderson, M.D.
Trial Contact Information:                                   
Diana Crean diana.crean@bassett.org 607-547-3073
Tari Miller, RN tari.miller@bassett.org 607-547-6373

 

 

PALLAS: PALbociclib Collaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer

 

For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
 
 
(Project 2039)
Eric Bravin, M.D.
Trial Contact Information:                                   
Diana Crean diana.crean@bassett.org 607-547-3073
Tari Miller, RN tari.miller@bassett.org 607-547-6373

 

 

A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

 

For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT02750826

 
(Project 2075)
Eric Bravin, M.D.
Trial Contact Information:                                   
Diana Crean diana.crean@bassett.org 607-547-3073
Tari Miller, RN tari.miller@bassett.org 607-547-6373

 

 

A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial

 

For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT02927249

 

(Project 2073)
Eric Bravin, M.D.
Trial Contact Information:                                   
Diana Crean diana.crean@bassett.org 607-547-3073
Tari Miller, RN tari.miller@bassett.org 607-547-6373

 

Colon Cancer

 
 
A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
 
For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT02912559

 

(Project 2082)
Eric Bravin, M.D.
Trial Contact Information:
Diana Crean diana.crean@bassett.org 607-547-3073
Tari Miller, RN tari.miller@bassett.org 607-547-6373

 


 

Glioblastoma Multiforme

 
 
A071102: A Phase II/III Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed Glioblastoma with MGMT Promoter Hypermethylation.
 

For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT02152982


(Project 2002)
Eric Bravin, M.D.
Trial Contact Information:
Diana Crean diana.crean@bassett.org 607-547-3073
Tari Miller, RN tari.miller@bassett.org 607-547-6373

 


 

Lung Cancer

 
 
A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

 

For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT02194738

 
(Project 1083)
Eric Bravin, M.D.
Trial Contact Information:
Diana Crean diana.crean@bassett.org 607-547-3073
Tari Miller, RN tari.miller@bassett.org 607-547-6373

 

 

E4512: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein 

 

For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT02201992


(Project 1085)
Eric Bravin, M.D.
Trial Contact Information:
Diana Crean diana.crean@bassett.org 607-547-3073
Tari Miller, RN tari.miller@bassett.org 607-547-6373

 

 

A081105: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

 

For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT02193282


(Project 1084)
Eric Bravin, M.D.
Trial Contact Information:
Diana Crean diana.crean@bassett.org 607-547-3073
Tari Miller, RN tari.miller@bassett.org 607-547-6373

 

 

EA5142: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

 

For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT02595944

 

(Project 2043)
Eric Bravin, M.D.
Trial Contact Information:
Diana Crean diana.crean@bassett.org 607-547-3073
Tari Miller, RN tari.miller@bassett.org 607-547-6373

 

 

RTOG 1306: A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)

 

For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT01822496

 

(Project 2040)
Joy Anderson, M.D.
Trial Contact Information:
Diana Crean diana.crean@bassett.org 607-547-3073
Tari Miller, RN tari.miller@bassett.org 607-547-6373

 

 

S1400: A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer 
(Lung-Map) 

 

For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT02154490


(Project 2000)
Eric Bravin, M.D.
Trial Contact Information:
Diana Crean diana.crean@bassett.org 607-547-3073
Tari Miller, RN tari.miller@bassett.org 607-547-6373

 


 

Melanoma

 
 
EA6134: A Randomized Phase III Trial of Dabrafenib +  Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma

 

For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT02224781

 

(Project 2020)
Eric Bravin, M.D.
Trial Contact Information:
Diana Crean diana.crean@bassett.org 607-547-3073
Tari Miller, RN tari.miller@bassett.org 607-547-6373

 

 

EA6141: Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

 

For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT02339571

 

(Project 2021)
Eric Bravin, M.D.
Trial Contact Information:
Diana Crean diana.crean@bassett.org 607-547-3073
Tari Miller, RN tari.miller@bassett.org 607-547-6373

 


 

Pancreatic

 
 
CanStem111P: A Phase III Study of BBI-608 plus nab-Paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Adenocarcinoma

 

For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT02993731

 

(Project 2076)
Eric Bravin, M.D.
Trial Contact Information:
Diana Crean diana.crean@bassett.org 607-547-3073
Tari Miller, RN tari.miller@bassett.org 607-547-6373

 

Prostate Cancer

 

RTOG 0924: Androgen Deprivation Therapy and High Dose Radiotherapy with or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

 

For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT02673190


(Project 1090)
Timothy Korytko, M.D.
Trial Contact Information:
Diana Crean diana.crean@bassett.org 607-547-3073
Tari Miller, RN tari.miller@bassett.org 607-547-6373

 


 

Blood Disorders

 
 
Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

 
For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT01688011


(Project 1067)
Eric Bravin, M.D.
Trial Contact Information:
Diana Crean diana.crean@bassett.org 607-547-3073
Tari Miller, RN tari.miller@bassett.org 607-547-6373

 

 

Myeloma: E1A11: Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
 

For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT01863550


(Project (1086)
Eric Bravin, M.D.
Trial Contact Information:
Diana Crean diana.crean@bassett.org 607-547-3073
Tari Miller, RN tari.miller@bassett.org 607-547-6373
  • MyHealthy Decisions | Total Ankle Replacement

    Jim Lambert loves to take long walks with his wife, but when pain from an old ankle injury made walking difficult, he started to look at surgical options. Jim's wife showed him an article in MyHealthy Decisions Magazine about the total ankle replacement surgeries that Bassett was doing, and he reread more

    MyHealthy Decisions | Robotic-Assisted Partial Knee Replacement

    James Flannery, of Oneonta, NY, was experiencing knee pain that was holding him back from work and doing the things he loves. After consultation with Dr. Michael Diaz, James opted for robotic-assisted partial knee replacement surgery using A.O. Fox Hospital's state-of-the-art NAVIO system. Watch read more

One Atwell Road Cooperstown, NY 13326

607-547-3456 : 1-800-BASSETT (227-7388)